一种新的人源化抗CD19嵌合抗原受体NK细胞的制备和对体外肿瘤细胞杀伤作用

摘要 目的：构建人源化抗CD19嵌合抗原受体NK细胞（hCAR19-NK）,并且在体外证明其对CD19 阳性血液病肿瘤细胞杀伤作用。方法：构建人源化的第二代CD19 CAR的逆转录病毒载体,使用辐照的K562-4-1BBL-mIL21细胞刺激外周血来源的NK细胞,通过逆转录病毒转导NK细胞获得hCAR19-NK细胞;采用流式细胞术和Western blot检测转导效率;采用4 h荧光杀伤实验和ELISA法检测hCAR19-NK细胞对淋巴瘤细胞的杀伤能力和IFN-γ释放水平;采用CD107a脱颗粒实验评估淋巴瘤细胞对hCAR19-NK细胞的特异性激活;比较对照组（Mock）和hCAR19-NK组细胞扩增倍数。结果：流式细胞术和Western blot 证明构建的CAR可以成功转导外周血来源的NK细胞;4 h荧光杀伤实验证明随着效靶比例升高,hCAR19-NK对Raji-GL杀伤率增加,明显高于Mock组;ELISA法检测显示Raji和K562-CD19作为靶细胞时,hCAR19-NK细胞的IFN-γ释放明显高于Mock组（P<0.01）;CD19⁺细胞（Raji和K562-CD19）可以特异性刺激hCAR19-NK细胞表达CD107a,具有统计学意义（P<0.05）;Mock组和hCAR19-NK组细胞扩增倍数无显著差异。结论：成功构建了可以杀伤CD19⁺ 肿瘤的人源化scFv的第二代hCAR19-NK细胞。     

基于逆转录病毒载体构建稳定表达人CD19和荧光蛋白的SW620细胞株

摘要 目的：构建表达人CD19和增强型绿色荧光蛋白（EGFP）和荧光素酶（LUC）的SW620细胞株。方法：构建MFG-CD19质粒,进行逆转录病毒载体包装,与MFG-EGFP-P2A-LUC逆转录病毒载体共同转导SW620细胞,筛选出稳定且强表达的单克隆细胞株SW620-CD19-EGFP-LUC并扩大培养。通过流式细胞术与qPCR技术检测细胞CD19的表达、通过荧光素酶法对细胞系表面荧光素酶的表达和细胞系功能进行鉴定。结果：流式检测构建完成的细胞株中CD19阳性的细胞占比为99.9%,EGFP阳性的细胞占比为99.2%;荧光显微镜下能够明显观察到细胞的绿色荧光;qPCR检测结果表明细胞株中CD19的表达水平相比原始细胞株明显上调,并且能够激活CD19 CAR-T细胞对其进行杀伤。结论：成功构建了能够稳定表达人CD19和荧光蛋白的SW620细胞株。     

卡瑞利珠单抗联合卡培他滨用于一线治疗复发转移鼻咽癌患者维持治疗疗效及对患者免疫功能的影响

摘要 目的：探讨卡瑞利珠单抗联合卡培他滨用于一线治疗复发转移鼻咽癌（NPC）患者维持治疗的疗效及对患者免疫功能的影响。方法：选取2020年1月至2022年1月钦州市第一人民医院收治的80例复发转移NPC患者,按照随机数字表法分为对照组和观察组,每组各40例。两组均接受吉西他滨联合顺铂化疗,对照组化疗后接受卡瑞利珠单抗单药维持治疗至1年,观察组化疗后接受卡瑞利珠单抗联合卡培他滨维持治疗至1年。比较两组疗效,不良反应,治疗前后B淋巴细胞亚群和自然杀伤（NK）细胞所占百分比的差异。结果：观察组客观缓解率（ORR）、疾病控制率（DCR）高于对照组（P＜0.05）。两组治疗后外周血CD5⁺B细胞、CD5⁺CD19⁺ B细胞、CD3^-CD56⁺NK细胞占比降低（P＜0.05）,但观察组治疗后外周血CD5⁺B细胞、CD5⁺CD19⁺ B细胞、CD3^-CD56⁺NK细胞占比高于对照组（P＜0.05）。两组Ⅲ度以上不良反应发生率比较差异无统计学意义（P＞0.05）。结论：卡瑞利珠单抗联合卡培他滨一线维持治疗复发转移NPC可提高临床疗效,减轻对细胞免疫功能的影响,且安全可靠。     

外周血T细胞CD38和HLA-DR的表达水平在儿童传染性单核细胞增多症中的临床意义

摘要 目的：探讨传染性单核细胞增多症（IM）患儿外周血T细胞活化分子CD38和人类白细胞抗原DR（HLA-DR）表达水平的临床意义。方法：采用流式细胞术分别检测45例IM患儿急性期和恢复期的活化分子CD38和HLA-DR在T细胞的表达水平,并与30例健康体检儿童进行对比。分析IM患儿急性期CD38和HLA-DR在T细胞的表达水平与EB病毒载量、肝功能指标、外周血异型淋巴细胞比例、淋巴细胞计数的相关性,并采用ROC曲线分析CD8⁺CD38⁺T和CD8⁺HLA-DR+T细胞百分比的诊断效能。结果：与对照组比较,IM急性期患儿的CD38和HLA-DR在T细胞的表达水平显著升高（P＜0.05）。CD8⁺CD38⁺T、CD8⁺HLA-DR+T细胞百分比分别与EBV-DNA、ALT、AST、LDH、异型淋巴细胞百分比、淋巴细胞计数呈正相关（P＜0.05）,与白蛋白（ALB）呈负相关（P＜0.05）;CD4⁺CD38⁺T、CD4⁺HLA-DR+T细胞百分比与上述指标无显著相关性（P均＞0.05）。IM恢复期CD38和HLA-DR在T细胞的表达水平较急性期明显降低（P＜0.05）。ROC曲线分析CD8⁺CD38⁺T、CD8⁺HLA-DR+T细胞百分比显示诊断儿童IM的AUC值分别为0.931和0.993,特异度均为100%,灵敏度分别为88.89 %和93.33 %。结论：流式法检测CD38和HLA-DR在T细胞的变化有助于判断病情变化。外周血CD8⁺CD38⁺T、CD8⁺HLA-DR+T细胞百分比不仅能反映出IM急性期肝功能损伤严重程度,还可作为儿童IM的流式诊断指标。     

反复呼吸道感染儿童血清维生素A、维生素E水平与免疫球蛋白、T淋巴细胞亚群、NK细胞及骨密度的关系分析

摘要 目的：探讨反复呼吸道感染（RRTI）儿童血清维生素A、维生素E水平与免疫球蛋白（Ig）、T淋巴细胞亚群、NK细胞及骨密度的关系。方法：选择2018年2月至2020年12月我院儿科收治的107例RRTI患儿（感染组）和83例同期于我院体检的健康儿童（对照组）为研究对象,检测两组血清维生素A、维生素E水平、Ig水平,外周血T淋巴细胞亚群、NK细胞占比以及骨密度。分析维生素A、维生素E与Ig、T淋巴细胞亚群、NK细胞及骨密度的相关性。结果：感染组血清维生素A、维生素E、IgG、IgA、IgM及外周血CD3⁺T细胞百分比、CD4⁺T细胞百分比、CD3^-CD56⁺ NK细胞百分比、CD56brightNK细胞百分比、CD56dimNK细胞百分比、桡骨和胫骨骨密度均低于对照组（P＜0.05）,外周血CD8⁺T细胞百分比高于对照组（P＜0.05）。血清维生素A及维生素E水平与外周血CD8⁺T细胞百分比呈负相关（P＜0.05）,与IgG、IgA、IgM水平,外周血CD3⁺ T细胞百分比、CD4⁺T细胞百分比、CD3^-CD56⁺ NK细胞百分比、CD56brightNK细胞百分比、CD56dimNK细胞百分比、桡骨和胫骨骨密度呈正相关（P＜0.05）。结论：RRTI患儿血清维生素A、维生素E水平明显降低,且与免疫功能障碍和骨密度降低有关。     

外周血Treg细胞、T淋巴细胞及其亚群与早期宫颈癌的关系及对淋巴结转移的预测价值研究

摘要 目的：分析外周血Treg细胞、T淋巴细胞及其亚群与早期宫颈癌的关系及对淋巴结转移的预测价值。方法：选择我院自2017年1月至2020年12月接诊的60例接受子宫颈癌根治术及盆腔淋巴清扫术的早期宫颈癌患者作为观察组,另选同期的60例健康体检者作为对照组。比较两组外周血Treg细胞、T淋巴细胞及其亚群水平,使用受试者工作特征曲线（ROC）下面积（AUC）评价外周血Treg细胞、T淋巴细胞及其亚群对淋巴结转移的预测效能。结果：观察组外周血Treg细胞、CD8⁺T细胞水平高于对照组,CD3⁺T细胞、CD4⁺T细胞、CD4⁺/CD8⁺比值均低于对照组（P＜0.05）;观察组术后外周血Treg细胞、CD8⁺T细胞水平较术前降低,CD3⁺T细胞、CD4⁺T细胞、CD4⁺/CD8⁺比值均较术前升高（P＜0.05）;在60例早期宫颈癌患者中,发生淋巴结转移12例;淋巴结转移组术前外周血Treg细胞水平、CD8⁺T细胞高于非淋巴结转移组,CD3⁺T细胞、CD4⁺T细胞、CD4⁺/CD8⁺比值均低于非淋巴结转移组（P＜0.05）;经多因素Logistic回归分析,外周血Treg细胞、CD3⁺T细胞、CD4⁺/CD8⁺比值均是早期宫颈癌患者发生淋巴结转移的独立预测因素（P＜0.05）;经ROC曲线分析,外周血Treg细胞、CD3⁺T细胞联合CD4⁺/CD8⁺比值预测早期宫颈癌患者发生淋巴结转移的AUC为0.910。结论：外周血Treg细胞、T淋巴细胞及其亚群水平与早期宫颈癌的病情演变有关,其中外周血Treg细胞、CD3⁺T细胞联合CD4⁺/CD8⁺比值预测淋巴结转移的效能较好,值得进一步研究应用。     

淋巴细胞及其亚群、NK细胞与儿童原发性免疫性血小板减少症复发的相关性研究

摘要 目的：为探讨淋巴细胞及其亚群、NK细胞与儿童原发性免疫性血小板减少症（ITP）复发的关系,评估其预测价值,为临床评估患者预后提供理论支持。方法：回顾性分析2017年12月-2021年12月于新疆医科大学第一附属医院儿科中心初发首诊为原发性免疫性血小板减少症的165例患儿,根据是否复发分为复发组与无复发组,评估ITP复发的影响因素,利用ROC曲线评估淋巴细胞计数绝对值对儿童ITP复发的预测价值,运用Kaplan-Meier法绘制与淋巴细胞计数绝对值相关的儿童ITP无复发生存曲线。结果：共纳入165名ITP患儿,复发率24.8%。淋巴细胞计数绝对值对儿童ITP无复发的ROC曲线下面积为0.704,95%CI为0.613-0.795（P＜0.05）,最佳截断值为3.21×10⁹/L。儿童ITP是否复发与年龄、淋巴细胞计数、出血评分、ESR有关,两组比较差异有统计学意义（P<0.05）。儿童ITP是否复发与CD3⁺CD19^-细胞计数、CD3⁺CD4⁺细胞计数、CD3⁺CD8⁺细胞计数、CD4⁺/CD8⁺细胞比例、NK细胞计数有关,两组比较差异有统计学意义（P<0.05）。结论：淋巴细胞计数绝对值可作为评估儿童ITP复发的预测指标,儿童ITP复发与初始T淋巴细胞亚群、NK细胞计数具有一定相关性。     

IL-7和胸腺基质细胞系(MTEC5)诱导胸腺CD3- CD4- CD8- 细胞分化

胸腺细胞发育是细胞因子及胸腺细胞与胸腺基质细胞相互作用的结果.观察了IL-7及小鼠胸腺基质上皮细胞系MTEC5对成年小鼠CD3^- CD4^- CD8^- 胸腺细胞发育的影响.IL-7能促进TN细胞增殖.TN细胞经在IL-7条件下培养后表达CD3-TCR分子,其中20％～40％为TCRγδ⁺,60％～80％为TCRαβ⁺,但保持CD4^- CD8^- .该细胞获得对 Con A、抗CD3mAb及抗TCRmAb进行增殖应答的能力,抗CD28mAb能促进这种增殖应答,证明表达的CD3-TCR分子功能成熟.当在该系统中加入MTEC5,部分TN细胞转变为CD3⁺TCRβ⁺CD4⁺CD8^- 和CD3⁺TCRβ⁺CD4^- CD8⁺SP细胞,表明MTEC5可诱导TN细胞分化为表现型成熟的胸腺细胞.     

组蛋白去乙酰化酶3对外周CD4+ T细胞分化的影响

目的 探讨组蛋白去乙酰化酶3（HDAC3）对外周CD4⁺ T细胞分化及功能的调控作用。方法 采用CD4cre酶介导Hdac3杂合基因缺失小鼠（Hdac3^fl/flCD4^cre+/-）及其野生型正常对照小鼠（Hdac3^fl/fl，WT），流式细胞术检测HDAC3缺失对外周CD4⁺和CD8⁺ T细胞比例和数量的影响；在体外佛波酯（PMA）和离子霉素（Ionomycin）刺激条件下，流式细胞术检测HDAC3缺失对CD4⁺ T细胞中IFN-γ、IL-4和IL-17A的表达以及Tfh细胞产生的影响；采用ELISA检测HDAC3缺失对小鼠血清IFN-γ、IL-4和IL-17表达的影响；分选Hdac3^fl/flCD4^cre+/-和WT小鼠外周初始CD4⁺ T细胞，分别在Th1和Th2分化条件下培养，细胞内染色检测HDAC3缺失对Th1、Th2以及Th17相关细胞因子及其特异转录因子表达的影响；采用Microarray检测HDAC3缺失对CD4⁺ T细胞分化亚群相关基因表达的影响；采用链脲佐菌素（STZ）处理小鼠构建I型糖尿病（TIDM）疾病模型，检测HDAC3缺失对T1DM发病的影响。结果 与WT小鼠相比，Hdac3^fl/flCD4^cre+/-小鼠外周CD4⁺和CD8⁺ T细胞的比例和数量显著降低。Hdac3^fl/flCD4^cre+/-小鼠CD4⁺ T细胞及血清中IFN-γ的表达显著降低，而IL-4和IL-17A的表达显著增加，Tfh细胞比例也显著增加；HDAC3缺失抑制体外培养CD4⁺ T细胞向Th1分化但促进其向Th2分化；Microarray检测发现HDAC3缺失导致Th1型细胞谱系基因表达降低，而Th2、Th17以及Tfh细胞谱系基因表达增加；在STZ诱导条件下，HDAC3缺失抑制小鼠T1DM的发生和CD4⁺ T细胞向Th1分化。结论 HDAC3促进外周CD4⁺ T细胞向Th1细胞分化并加重T1DM的发生。     

肝癌肿瘤干细胞的分离鉴定及差异性小分子RNA筛选

旨在分离并鉴定肝癌肿瘤干细胞,并对其异常表达的microRNA进行了初步筛选。首先利用流式细胞术及免疫荧光技术分别在肝癌细胞系及肝癌组织标本中确认了CD90⁺细胞的存在;随后利用免疫磁珠分选技术从肝癌细胞系MHCC97-H中分离出了CD90⁺细胞,化疗药物耐药性实验表明,CD90⁺细胞具有明显的化疗药物耐受能力;两次裸鼠皮下成瘤性实验也表明CD90⁺细胞具有较强的成瘤能力,而CD90^-细胞不具备成瘤能力。上述实验充分说明:CD90⁺细胞具有肝癌肿瘤干细胞特性。因此利用该细胞模型进行了肝癌肿瘤干细胞CD90⁺细胞和非肝癌肿瘤干细胞CD90^-细胞之间差异表达的microRNA的检测,结果表明,CD90⁺细胞与CD90^-细胞之间共有92个microRNAs的表达存在差异性,其中在CD90⁺细胞中高表达的microRNAs有52个;在CD90^-细胞中高表达的microRNAs有40个。     

稳定表达CD19-FLUC-GFP的CT26细胞系的构建及鉴定

实体瘤缺乏明确的嵌合抗原受体T细胞(chimeric antigen receptor T-cell, CAR-T)治疗靶点。因此,通过慢病毒将已经明确的靶点分子CD19带入实体瘤细胞系,研究CD19 CAR-T细胞对其的杀伤,能够为CAR-T细胞针对实体瘤的治疗提供潜在的支撑。本研究利用三质粒慢病毒系统构建了稳定表达CD19、萤火虫荧光素酶(firefly luciferase, FLUC)和绿色荧光蛋白(green fluorescent protein, GFP)的结肠癌CT26细胞系CT26-CD19-FLUC-GFP。该细胞系与CT26细胞系的生长活性一致。通过流式细胞术检测不同代次CT26-CD19-FLUC-GFP细胞,证实了CT26-CD19-FLUC-GFP细胞连续传代至第5、10、22代后CD19及GFP的稳定表达。进一步证实,连续传代至第22代的CT26-CD19-FLUC-GFP细胞中的CD19 mRNA及FLUC表达水平显著高于对照组CT26细胞。与T细胞相比,CD19 CAR-T细胞能够显著杀伤CT26-CD19-FLUC-GFP细胞及MC38-CD19细胞。CT26-CD19-FLUC-GFP细胞腹腔植入小鼠体内1周后,通过活体成像仪可以检测到腹腔区域的FLUC表达。上述结果表明,成功构建了稳定表达CD19-FLUC-GFP的CT26细胞系,且该细胞系能够被CD19 CAR-T细胞特异性杀伤。     

Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays

Background aimsNK-92, a permanent natural killer (NK) cell line, shows cytotoxicity against a variety of tumors and has been tested in a phase I trial. We tested the toxicity of NK-92 and chemotherapy drugs against the stem cell capacity of the acute leukemia cell line, KG1. While the chromium-release assay is the most common method for assessing cytotoxicity of immune effectors, and flow cytometry is increasingly used, the relationship of either assay to clonogenic readouts remains unknown.MethodsKG1 was assessed for stem cell frequency by serial dilution, single-cell sorting and colony growth in methylcellulose. KG1 was sorted into CD34⁺ CD38⁺ and CD34⁺ CD38^? populations and recultured in liquid medium or methylcellulose to determine the proliferative capacity of each fraction. Cytotoxicity of NK-92, daunorubicin and cytarabine against KG1 was measured using the chromium-release assay, flow cytometry and clonogenic assays.ResultsThe culture-initiating cell frequency of whole KG1 was between 1 in 100 to 1000 by serial dilution and single-cell sorting. Although a rare (1–3%) CD34⁺ CD38^? population could be demonstrated in KG1, both fractions had equivalent proliferative capacity. The cumulative flow cytotoxicity assay was more sensitive than the chromium-release assay in detecting target cell killing. At a 10:1 ratio NK-92 eliminated the clonogenic capacity of KG1, which was not predicted by the chromium-release assay.ConclusionsClonogenic assays provide a more sensitive means of assessing the effect of a cytotoxic agent against putative cancer stem cells within cell lines, provided that they grow well in liquid culture medium or methylcellulose.     

Implication of different effector mechanisms by cord blood–derived and peripheral blood–derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines

Background aimsCytokine-induced killer (CIK) cells ex vivo–expanded from cord blood (CB) or peripheral blood (PB) have been shown to be cytotoxic against autologous and allogeneic tumor cells. We have previously shown that CD56⁺ CIK cells (CD3⁺CD56⁺ and CD3⁻CD56⁺) are capable of killing precursor B-cell acute lymphoblastic leukemia (B-ALL) cell lines. However, the lytic pathways used by CD56⁺ PB and CB-CIK cells to kill B-ALL cell lines have not been studied.MethodsCB and PB-CIK cells were differentiated. CD56⁺ CB- and PB-CIK cells were compared for expression of different phenotypic markers and for the lytic pathways used to kill B-ALL cell lines.ResultsWe found that cytotoxic granule proteins were expressed at higher levels in CD56⁺ PB-CIK than in CD56⁺ CB-CIK cells. However, CD56⁺ CB-CIK cells expressed more tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) compared with CD56⁺ PB-CIK cells. We observed that CD56⁺ CB-CIK cells used both the NKG2D and TRAIL cytotoxic pathways and were more effective at killing REH cells than CD56⁺ PB-CIK cells that used only the NKG2D pathway. In contrast, CD56⁺ PB-CIK cells used both NKG2D and TRAIL pathways to kill NALM6 cells, whereas CD56⁺ CB-CIK cells used only the NKG2D pathway.ConclusionsOur results suggest that both the source of CIK and the type of B-ALL cell line have an impact on the intensity of the cytolytic activity and on the pathway used. These findings may have clinical implications with respect to optimizing therapeutic efficacy, which may be dependent on the source of the CIK cells and on the target tumor cells.     

Peripheral regulatory cells immunophenotyping in Primary Sj?gren's Syndrome: a cross-sectional study

Introduction

IL-10--producing B cells, Foxp3-expressing T cells (Tregs) and the IDO-expressing dendritic cells (pDC) are able to modulate inflammatory processes, to induce immunological tolerance and, in turn, to inhibit the pathogenesis of autoimmune disease.The aim of the study was to characterize and to enumerate peripheral IL-10--producing B cells, Tregs and pDCregs in primary Sjögren''s Syndrome (pSS) patients in regard of their clinical and serologic activity.

Methods

Fifty pSS patients and 25 healthy individuals were included in the study. CD19⁺--expressing peripheral B lymphocytes were purified by positive selection. CD19⁺/CD24^hi/CD38^hi/IL-10--producing B cells, CD4⁺/CD25^hi/Foxp3⁺ and CD8⁺/CD28^-/Foxp3⁺ Tregs, as well as CCR6⁺/CD123⁺/IDO⁺ DCs, were quantitated by flow cytometry.

Results

Immature/transitional circulating IgA⁺ IL-10--producing B cells had higher levels in pSS patients versus control group, whereas CD19⁺/CD38^hi/IgG⁺/IL-10⁺ cells had lower percentage versus control. Indeed CD19⁺/CD24^hi/CD38^hi/CD5⁺/IL-10⁺, CD19⁺/CD24^hi/CD38^hi/CD10⁺/IL-10⁺, CD19⁺/CD24^hi/CD38^hi/CD20⁺/IL-10⁺, CD19⁺/CD24^hi/CD38^hi/CD27^-/IL-10⁺, and CD19⁺/CD24^hi/CD38^hi/CXCR7⁺/IL-10⁺ cells had higher frequency in clinical inactive pSS patients when compared with control group. Remarkably, only percentages of CD19⁺/CD24^hi/CD38^hi/CD10⁺/IL-10⁺ and CD19⁺/CD24^hi/CD38^hi/CD27^-/IL-10⁺ subsets were increased in pSS serologic inactive versus control group (P < 0.05). The percentage of IDO-expressing pDC cells was higher in pSS patients regardless of their clinical or serologic activity. There were no statistically significant differences in the percentage of CD4⁺/CD25^hi/Foxp3⁺ Tregs between patient groups versus controls. Nonetheless, a decrease in the frequency of CD8⁺/CD28^-/Foxp3⁺ Tregs was found in inactive pSS patients versus controls (P < 0.05).

Conclusions

The findings of this exploratory study show that clinical inactive pSS patients have an increased frequency of IL-10--producing B cells and IDO-expressing pDC cells.     

Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity

Background aimsKey obstacles in human iNKT cell translational research and immunotherapy include the lack of robust protocols for dependable expansion of human iNKT cells and the paucity of data on phenotypes in post-expanded cells.MethodsWe delineate expansion methods using interleukin (IL)-2, IL-7 and allogeneic feeder cells and anti-CD2/CD3/CD28 stimulation by which to dependably augment Th2 polarization and direct cytotoxicity of human peripheral blood CD3⁺Vα24⁺Vβ11⁺ iNKT cells.ResultsGene and protein expression profiling demonstrated augmented Th2 cytokine secretion (IL-4, IL-5, IL-13) in expanded iNKT cells stimulated with anti-CD2/CD3/CD28 antibodies. Cytotoxic effector molecules including granzyme B were increased in expanded iNKT cells after CD2/CD3/CD28 stimulation. Direct cytotoxicity assays using unstimulated expanded iNKT cell effectors revealed α-galactosyl ceramide (α-GalCer)-dependent killing of the T-ALL cell line Jurkat. Moreover, CD2/CD3/CD28 stimulation of expanded iNKT cells augmented their (α-GalCer-independent) killing of Jurkat cells. Co-culture of expanded iNKT cells with stimulated responder cells confirmed contact-dependent inhibition of activated CD4⁺ and CD8⁺ responder T cells.DiscussionThese data establish a robust protocol to expand and novel pathways to enhance Th2 cytokine secretion and direct cytotoxicity in human iNKT cells, findings with direct implications for autoimmunity, vaccine augmentation and anti-infective immunity, cancer immunotherapy and transplantation.     

An age‐related numerical and functional deficit in CD19+CD24hiCD38hi B cells is associated with an increase in systemic autoimmunity

Autoimmunity increases with aging indicative of reduced immune tolerance, but the mechanisms involved are poorly defined. In recent years, subsets of B cells with immunoregulatory properties have been identified in murine models of autoimmune disorders, and these cells downregulate immune responses via secretion of IL10. In humans, immature transitional B cells with a CD19⁺CD24^hiCD38^hi phenotype have been reported to regulate immune responses via IL10 production. We found the frequency and numbers of CD19⁺CD24^hiCD38^hi cells were reduced in the PBMC pool with age. IL10 expression and secretion following activation via either CD40, or Toll‐like receptors was also impaired in CD19⁺CD24^hiCD38^hi B cells from healthy older donors. When investigating the mechanisms involved, we found that CD19⁺CD24^hiCD38^hi B‐cell function was compromised by age‐related effects on both T cells and B cells: specifically, CD40 ligand expression was lower in CD4 T cells from older donors following CD3 stimulation, and signalling through CD40 was impaired in CD19⁺CD24^hiCD38^hi B cells from elders as evidenced by reduced phosphorylation (Y705) and activation of STAT3. However, there was no age‐associated change in expression of costimulatory molecules CD80 and CD86 on CD19⁺CD24^hiCD38^hi cells, suggesting IL10‐dependent immune suppression is impaired, but contact‐dependent suppressive capacity is intact with age. Finally, we found a negative correlation between CD19⁺CD24^hiCD38^hi B‐cell IL10 production and autoantibody (Rheumatoid factor) levels in older adults. We therefore propose that an age‐related decline in CD19⁺CD24^hiCD38^hi B cell number and function may contribute towards the increased autoimmunity and reduced immune tolerance seen with aging.     

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

PurposeAcute myeloid leukemia (AML) is a highly heterogeneous neoplastic disease with a poor prognosis that relapses even after its treatment with chimeric antigen receptor (CAR)-T cells targeting a single antigen. CD123 and CLL1 are expressed in most AML blasts and leukemia stem cells, and their low expression in normal hematopoietic stem cells makes them ideal targets for CAR-T. In this study, we tested the hypothesis that a new bicistronic CAR targeting CD123 and CLL1 can enhance antigenic coverage and prevent antigen escape and subsequent recurrence of AML.MethodsCD123 and CLL1 expressions were evaluated on AML cell lines and blasts. Then, in addition to concentrating on CD123 and CLL1, we introduced the marker/suicide gene RQR8 with a bicistronic CAR. Xenograft models of disseminated AML and in vitro coculture models were used to assess the anti-leukemia efficacy of CAR-T cells. The hematopoietic toxicity of CAR-T cells was evaluated in vitro by colony cell formation assays. It was demonstrated in vitro that the combination of rituximab and NK cells caused RQR8-mediated clearance of 123CL CAR-T cells.ResultsWe have successfully established bicistronic 123CL CAR-T cells that can target CD123 and CLL1. 123CL CAR-T cells effectively cleared AML cell lines and blasts. They also demonstrated appreciable anti-AML activity in animal transplant models. Moreover, 123CL CAR-T cells can be eliminated in an emergency by a natural safety switch and don't target hematopoietic stem cells.ConclusionsThe bicistronic CAR-T cells targeting CD123 and CLL1 may be a useful and secure method for treating AML.     

CD19 chimeric antigen receptor–redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide–derived dendritic cell vaccine in leukemia

BackgroundChimeric antigen receptor (CAR)–T cell therapy opens a new era for cancer treatment. However, in prolonged follow-up, relapse has emerged as one of the major obstacles. Dendritic cell (DC) vaccination is a promising treatment to eradicate tumor cells and prevent relapse. The epidermal growth factor receptor (EGFR) pathway substrate 8 (Eps8) gene is involved in regulating cancer progression and is considered an attractive target for specific cancer immunotherapy. The purpose of this study was to explore a combinatorial therapy using CAR-T cells and a DC vaccine such as Eps8-DCs to increase leukemia treatment efficacy.MethodsWe pulsed DCs with Eps8-derived peptides to generate Eps8-DCs, engineered T cells to express a second-generation CAR specific for CD19, and analyzed the effects of the Eps8-DCs on the in vitro expansion, phenotype and effector functions of the CD19 CAR-T cells.ResultsThe Eps8-DCs significantly reduced the activation-induced cell death and enhanced the proliferative potential of CAR-T cells during in vitro expansion. In addition, the expanded T cells co-cultured with the Eps8-DCs exhibited an increased percentage of central memory T cells (Tcms) and a decreased percentage of effector memory T cells (Tems). The Eps8-DCs enhanced CD19 CAR-T cell immune functions, including cytokine production, CD107a degranulation activity and cytotoxicity.DiscussionThis study demonstrates that Eps8-DCs exert synergistic effect on CD19 targeting CAR-T cells and paves the way for clinical trials using the combination of DC vaccination and engineered T cells in relapsed leukemia.     

Characterization of natural killer cell activity in Macaca nemestrina

Natural killer (NK) cell activity was evaluated in three groups of Macaca nemestrina that varied with respect to SAIDS D retrovirus serotype 2 (SRV-2/W) and viremic status. Target cells used were Raji and K562 cells. No significant differences (ANOVA) in mean NK activity were detected among the three groups of animals studied. Using Raji targets, mean LU₃₀/10⁶ ± SEM was 6.3 ± 1.6 for seronegative (V-Ab−) animals, 7.3 ± 1.5 for seropositive (V-Ab+) animals, and 10.2 ± 3.5 for persistently viremic (V + Ab−) animals. Using K562 targets, mean LU₃₀/10⁶ was 7.6 ± 1.7 for seronegative (V-Ab−) animals, 6.5 ± 2.5 for seropositive (V-Ab+) animals, and 5.1 ± 1.9 for persistently viremic (V+Ab−) animals. Percentage blood CD16⁺ and CD8⁺cells also were not different in the three groups of animals. NK activity did not always correlate with percentage of CD16⁺ or CD8⁺ cells in peripheral blood at the time the assays were done. In persistently viremic animals, there was a strong positive correlation between percent CD16⁺ and CD8⁺ cells and NK activity using K562 cells but not Raji cells. Depletion experiments indicated that lysis was mediated by both CD8⁺ and CD16⁺ cells with both Raji and K562 cells. However, Raji targets were a better indicator of killing mediated by CD16⁺ cells. Our studies indicate that M. nemestrina may be classified as high or low responders with regard to NK activity, and there was no correlation with SRV-2/W viral or antibody status. Additionally, our results suggested that group housing of M. nemestrina was usually associated with increased NK activity. In conclusion, studies of NK activity in M. nemestrina should consider target cells used, phenotype of effectors, endogenous (high or low) levels of NK activity in individual animals, and housing conditions. © 1996 Wiley-Liss, Inc.